 Models predict that royalties will rise from £25.6 million in FY2022 to £75.2 in FY2027.Ridinilazole has been de-risked with positive Phase 2 data.Summit Therapeutics estimates that the price will be $1,200 for one course of therapy in the US and approximately 20% less in the EU.